NeuroPace Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-31.51	-32.96	-47.08	-36.08	-24.28	-29.97
Depreciation & Amortization	1.63	1.61	2.99	0.3	0.31	0.42
Share-Based Compensation	9.97	9.56	8.35	4.29	1.38	1.44
Other Operating Activities	2.37	2.09	-1.12	6.92	0.98	3.08
Operating Cash Flow	-17.53	-19.7	-36.87	-24.58	-21.61	-25.03
Capital Expenditures	-0.15	-0.17	-0.6	-0.38	-0.06	-0.46
Change in Investments	15.5	23.2	24.4	-85.01	-10.71	4.08
Investing Cash Flow	15.36	23.03	23.8	-85.4	-10.77	3.62
Share Issuance / Repurchase	9.41	8.69	0.9	110.01	0.01	0.04
Debt Issued / Paid	0	0	0	-4.09	23.51	21.33
Other Financing Activities	-0.96	-0.56	-0.41	-3.39	31.49	-
Financing Cash Flow	8.45	8.13	0.49	102.53	55.01	21.37
Net Cash Flow	6.28	11.45	-12.58	-7.45	22.63	-0.04
Free Cash Flow	-17.68	-19.87	-37.47	-24.96	-21.67	-25.49
Free Cash Flow Margin	-25.59%	-30.38%	-82.32%	-55.24%	-52.68%	-68.94%
Free Cash Flow Per Share	-0.63	-0.77	-1.52	-1.50	-106.19	-126.23

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).